Profiling CARD14 gene expression in Indian Psoriasis patients Authors: S. Singh, D. Pradhan, P. Puri, Shruti Sharma, A. K. Jain Published: 2024 ABSTRACT Several Genome Wide linkage Studies on psoriasis performed to gain insight of genetic architecture of the disease. Caspase Recruitment Domain-containing family 14 (CARD14) also known as CARMA2 or BIMP2; cytogenic location: 17q25.3, is a scaffold protein that primarily controls the skin epidermis’s nuclear factor kB (NF-kB) signaling pathway activity in skin epidermis, a master gene for inflammation, has been shown to be linked with rare, heritable form of psoriasis. CARD14 is predominantly expressed in keratinocytes and epithelial cells, but also in unidentified dermal cells. For better understanding of molecular processes involved in CARD14 underlying Indian psoriatic patients, we analyzed gene expression of 42 moderates to severe cases of plaque psoriasis and same number of controls using qPCR and its validation through Immunohistochemistry (IHC). This study identifies that the expression of CARD14 in dermal endothelial cells among patients with psoriasis and explores the potential functional consequences associated with an overactive CARD14 gene. Furthermore, the expression data from the western population was consistent with the results of the qPCR validation of the candidate gene. There is a significant correlation between Indian psoriasis vulgaris patients and CARD14 up-regulation, as evidenced by a roughly two-fold shift in lesional tissue expression. This provides insights into the pathways and genes linked to the pathogenesis of psoriasis. Introduction Chronic plaque psoriasis also known as Psoriasis vulgaris (PsV) is the most prevalent manifestation amongst all clinical presentations of psoriasis disease1. It represents a chronic inflammatory, autoimmune skin condition characterized by robust genetic influences, impacting 0% and 11% of the global population across diverse geographical latitudes2–4, whereas affecting 2-2.8% in Indian population. The advancement of psoriatic lesions is instigated by the dysregulation of the innate immune system, marked by the altered differentiation and extensive keratinocytes (KC) proliferation and the infiltration of innate immune cells5. Psoriasis is a genetically complex disease that makes it difficult to completely understand its etiology. Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, also contribute to the regulation of gene expression, influencing both immune responses and keratinocyte behavior. These epigenetic alterations can be shaped by environmental factors such as stress, infections, and lifestyle, which in turn modify disease risk and severity. Epigenetic regulation is pivotal for keratinocyte differentiation, and its dysregulation can contribute to psoriatic pathogenesis6. The strict interactions between genetic susceptibility and epigenetic modifications are central to understanding psoriasis, as they together shape the epidermal barrier dysfunction and immune hyperactivation seen in the disease6,7. The hallmark of psoriasis is KCs proliferation and differentiation, subsequently psoriasis-increased genes include CARD14, as highly expressed in keratinocytes present in skin epidermis encodes a nuclear factor (NF)-kB activator. Through initial studies it was suggested that CARD14 is mainly expressed in placenta but later on it has been revealed that CARD14 is mainly expressed in mucosa tissue8. Lately, researchers have demonstrated that epidermal keratinocytes express CARD149,10. In typical stable conditions, NF-kB remains localized within the cytoplasm, restrained by the inhibitor IkB. However, when NF-kB signaling is activated, IkB undergoes phosphorylation by IkB kinase (IKK), leading to degradation of IkB. This facilitates the liberation and triggering of NF-kB8,11. Bowcock and colleagues discovered that CARD14 resides within the psoriasis susceptibility locus 2 (PSORS2). Adaptive immune system and interleukin (IL)-17/IL-23 axis play key roles in PsV, an intense inflammatory response resulting from innate immunity hyperactivation, with prominent involvement of the IL-36 axis are characteristics of pustular psoriasis (PP). CARD14 and IL36RN mutations have been identified as important contributors to the pathogenesis of both PP, acute generalized PP (GPP) and PsV. In GPP, gain-of-function mutations in CARD14 lead to the activation of pro-inflammatory signaling pathways, particularly the NF-κB and MAPK pathways, resulting in increased production of inflammatory cytokines, such as IL-1β, IL-36, and TNF-α, which drive the neutrophilic infiltration characteristic of pustular lesions. This highlights CARD14’s pivotal role in mediating the severe inflammatory responses seen in these forms of psoriasis12,13. In an RNAseq study, differential upregulation of CARD14 mRNA was observed in psoriatic lesions14. Cumulatively, these findings imply that CARD14 might contribute to the pathogenesis of psoriasis in common as well as in those who have CARD14 mutations linked to the disease10,15–17. CARD14 resulting is recognized for its role as a scaffold protein, engaging with molecules participating in NF-kB signaling to create a complex alongside Bcl10, MALT1 and TRAF2. This complex helps to bring in downstream signaling elements, which in turn triggers the activation of NF-kB and MAPK signaling. These signaling pathways are pivotal factors in the pathophysiology of psoriasis8,18–20. Jordan et al. found that missense mutations linked to psoriasis in wild-type CARD14 caused an additional increase in NF-kB activation21. Important chemokines linked to psoriasis, such as IL36G, IL8 and CCL20, are induced in this way. The proteins derived from these transcripts possess the ability to attract immune cells linked to disease’s etiology22,23. Several chemokines were expressed when dermal endothelium cells were exposed to psoriatic cytokines in culture, including TNFα, IL-17, and IFNγ, like those upregulated following transfections of endothelial cells with mutations associated with psoriasis-linked CARD1425–27. Furthermore, it was found that co-localization of these numerous chemokines with dermal endothelial cells in their native environment and was enhanced in psoriatic lesions27. Therefore, CARD14 may have a major role in the pathophysiology of psoriasis, in part because of its pro-inflammatory effects on dermal endothelial cells12. The incorporation of these details enhances the understanding of how expession and genetic mutations, such as those in CARD14, contribute to the disease’s clinical manifestations and provides a foundation for exploring gene expression and targeted therapeutic strategies in Indian population. Methodology Subjects For this study in total eighty six (86), clinically confirmed PsV patients were recruited. This case-control study encompassed histologically confirmed cases of PsV and an equivalent number of controls. All subjects with PsV were enrolled between May 2018-February 2020. All cases underwent clinical and histopathological confirmation by a minimum of two dermatologists. Controls consisted of unaffected individuals without a family history of psoriasis. Comprehensive primary clinical data were thoroughly recorded. This included demographic information, age and its emergence (early (≤ 40 years) or late onset (> 40), familial history, severity range of psoriatic skin lesions assessed by PASI (Psoriasis Area and Severity Index) score. The Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, (IEC/VMMC/SIH/Project/2018/1094) Institutional Ethical Committee, granted the approval for this study. Skin biopsies were collected from individuals with psoriasis, adhering to the approved protocol, and every participant in the study provided informed consent. The whole sample collections and experiments were performed adhering to the guidelines and regulations. Collections and extraction of tissue and RNA Out of 86 enrolled patients, peri-lesional skin tissues from 42 cases underwent qRT-PCR (quantitative reverse transcription polymerase chain reaction) for processing of gene expression and immunohistochemistry (IHC). The remaining patients were not included in the study because their RNA quality was low and they were not histopathologically confirmed. 5 mm punch biopsy was obtained from each participant and instantly divided into two fragments. First section was preserved in RNA later and kept for gene expression research at − 80 °C, while the second section was fixed in buffered formalin for histopathological confirmation. The sample sets were subsequently forwarded to the National Institute of Pathology (ICMR) for additional processing, including histopathological confirmation, mRNA expression analysis, and IHC. RNA isolation from tissue samples Perilesional skin tissue samples were used to extract RNA using AllPrep DNA/RNA Mini Kit of Qiagen. β- mercaptoethanol (10 µl) was freshly added to buffer RLT Plus (1 ml) just before use. 5–10 mg of biopsy samples soaked in RNA later, and then crushed using mortar and pestle. The resulted tissue’s paste were subsequently moved to 1.5 ml micro centrifuge tubes (MCTs) and mixed with RLT buffer added with β-mercaptoethanol (600 µl) and thoroughly blended. Subsequently, the lysate is transferred to QIAshredder column positioned atop a Qiagen’s collection tube (2 ml). Then the samples were centrifuged (13,000 rpm for 2 min at RT). Without interfering with the flow-through, the pulverized lysate was extracted and moved to an AllPrep DNA spin column that was set up on a 2 ml collection tube. One minute of 10,000 rpm centrifugation was carried out at RT. While the flow-through underwent RNA isolation processes, the DNA spin column was utilized for DNA isolation. It was combined with 600 µl of 70% ethanol, moved to a RNeasy spin column, and centrifuged for one minute at 10,000 rpm. After that, 700 µl of buffer RW1 (reconstitute with ethanol) were used to wash the spin columns, and they were centrifuged. Following two rounds of washing with 500 µl of buffer RPE (reconstituted with ethanol), the columns were centrifuged for two minutes at room temperature at 10,000 rpm to get rid of the ethanol. RNA was extracted from the columns using 50 µl of RNase-free water, and the mixture was centrifuged for one minute at 10,000 rpm after the columns were moved to 1.5 ml MCTs. To boost RNA concentration, the elution procedure was performed again using the same elute. Isolated RNA stored at -80 °C and processed further. Thermo Scientific, (Waltham, MA, USA), used the Nanodrop 2000 Spectrophotometer to quantify the eluted RNA. cDNA synthesis Thermo Scientific’s RevertAid First Strand cDNA Synthesis Kit was used to create cDNA from about 1 µg of total RNA. Nuclease-free H2O was used to dilute 1 µg of RNA to a volume of 12 µl. This was then combined with the kit’s included oligo dT primers (1 µl), 5X buffer (4 µl), dNTPs (2 µl), RNase inhibitor (1 µl), and reverse transcriptase (1 µl) to create an aggregate volume of 20 µl. The conditions for synthesizing cDNA were as follows: heating the enzymes for five minutes at 65 °C, then for sixty minutes at 42 °C, denaturing them for five minutes at 70 °C, and finally for an infinite hold at 4 °C. The final concentration of cDNA was around 50 ng/µl. Gene expression study by quantitative PCR using Taqman probes After diluting the cDNA product five times with ddH2O, approximately 10 ng was utilized for every qRT-PCR assay. Transcripts were quantified using an Applied Biosystems 7900HT Fast Real-Time PCR equipment with a Taqman probe-primer set purchased from Applied Biosystems CARD14 (Hs00364499_ml). In all other gene expression studies, transcripts were quantified using Applied Biosystems’ TaqMan Universal PCR Master Mix in a 20 µl reaction with 1 µl of probe. Following that, standard PCR settings were used, which included 10 min at 95 °C, 40 cycles of 15 s at 95 °C and 30 s at 60 °C, and an analysis of the dissociation curve using 15 s at 95 °C, 15 s at 60 °C, and 15 s at 95 °C. A 96-well plate from ABI in Foster City, California was used to run each sample in triplicate. Melting curve analysis using StepOne software v.2.3 (ABI, Foster City, CA) was used to confirm the probe specificity. Gene expression’s normalization was determined by expression fold change of GAPDH gene in the involved skin compared to uninvolved skin of same patient. Using DataAssist software v.3.01 (ABI, Foster City, CA), the mean Ct for each gene was normalized with endogenous control (GAPDH) to get ΔCt. The fold change (FC) was then computed using the 2ΔΔCt approach. Immunohistochemistry analysis Validation of samples were carried out through IHC, using Novo link Polymer detection systems (Leica Bio systems). Tissue blocks embedded in paraffin and treated in formalin were used to create thin sections with a thickness of 4 μm. Paraffin was removed by dipping the slides inside Coplin jars containing Xylene (Merck) for 30 min (two changes for 15 min). The portions were then gradually rehydrated by being kept for 15 min each in Coplin jars with gradients of ethanol (Xylene 95% Ethanol, 70% Ethanol, 50% Ethanol, and lastly dH2O). To extract the antigen, slides were then boiled in a 10 mM sodium citrate solution containing 0.05% Tween 20 for 20 min. After that, slides were progressively cooled under running water, cleaned with TBS, and blocked for two hours at room temperature using the Protein Block buffer that included with the kit. Tissue sections were marked with mini-PAP pen (Invitrogen) to allow for minimum reagent usage. The blocking buffer was decanted, the primary antibody [CARD14 (1:150)] was added and left intact overnight at 4 °C in a wet chamber. Slides were rinsed three times with TBS for five minutes each the next day. Peroxidase block was added for 15 min to neutralize endogenous peroxidase activity, followed by wash in TBS 2 times and incubation with post- primary block for 30 min. After wash, polymer was added and incubated for 30 min to allow detection of mouse and rabbit primary antibodies by the polymer system. After washing the polymer by 2 washes in TBS, AEC working solution was added and incubated for 5 min. AEC slides washed in water and were counter-stained for 2 min with hematoxylin. Hematoxylin was washed with water for 5 min, and then slides were gradually dehydrated using grades of ethanol. After incubation in xylene for 15–30 min, slides were mounted using CC mount, allowed to dry and then observed under microscope and image was captured. All the 42 disease sections were histopathologically confirmed as plaque psoriasis/PsV. Results Study subjects The research involved 42 patients diagnosed with PsV. Skin biopsies were obtained from both peri-lesional sites, representing psoriasis-involved (case) and uninvolved sites (control). Histopathological confirmation was conducted for clinically diagnosed cases. The patients’ mean age was 33.5 years, and the male-to-female ratio was 1:0.75. Family history was reported in 21% of psoriasis cases, and 52.3% of cases exhibited autoimmune diseases as comorbid conditions. Table 1 provides a comprehensive display of the clinical and demographic dispersion. Table 1; Fig. 1 provide a summary and visual representation of the attributes of the various groupings respectively. Table 1Demographic and clinical characterisation of patients with psoriasis.Variablen = 42AgeType-1 (< 40 Yrs)25Type-2(> 40 Yrs)17Ratio1:0.75Mean age33.57Sex, n (%)Male24 (57)Female18 (43)Duration of the disease in monthsRange7−480Mean ± SD97.26 ± 106.49Family history, n (%)─ ve33 (78.6)+ ve9 (21.4)Comorbidity, n (%)Present22 (52.38)Absent20 (47.6)Distribution, n (%)Elbow/Fore arms/ Upper/Lower Limb6 (14.28)Trunk + Scalp/Face8 (19.04)Back + Fore arm/Limb9 (21.42)Fore arms/U/L Limb + Scalp/Face4 (9.52)Trunk/Back + Scalp/Face + Upper/Lower Limb15 (35.7)Duration in which skin biopsy sample is collectedMay 2018–Feb 2020 Table 1Demographic and clinical characterisation of patients with psoriasis.Variablen = 42AgeType-1 (< 40 Yrs)25Type-2(> 40 Yrs)17Ratio1:0.75Mean age33.57Sex, n (%)Male24 (57)Female18 (43)Duration of the disease in monthsRange7−480Mean ± SD97.26 ± 106.49Family history, n (%)─ ve33 (78.6)+ ve9 (21.4)Comorbidity, n (%)Present22 (52.38)Absent20 (47.6)Distribution, n (%)Elbow/Fore arms/ Upper/Lower Limb6 (14.28)Trunk + Scalp/Face8 (19.04)Back + Fore arm/Limb9 (21.42)Fore arms/U/L Limb + Scalp/Face4 (9.52)Trunk/Back + Scalp/Face + Upper/Lower Limb15 (35.7)Duration in which skin biopsy sample is collectedMay 2018–Feb 2020 Demographic and clinical characterisation of patients with psoriasis. Fig. 1Typical histological and clinical characteristics of psoriasis vulgaris (PsV). (a, b) Well-demarcated silvery-white scaly, erythematous plaques are observed. (c, d) Histopathological characteristics of typical psoriasis lesion in a PsV patients. Photomicrographs showed hyperkeratosis with parakeratosis and neutrophilic crusts (H&E; 200X). Typical histological and clinical characteristics of psoriasis vulgaris (PsV). (a, b) Well-demarcated silvery-white scaly, erythematous plaques are observed. (c, d) Histopathological characteristics of typical psoriasis lesion in a PsV patients. Photomicrographs showed hyperkeratosis with parakeratosis and neutrophilic crusts (H&E; 200X). CADR14 expression in lesional and non-lesional punch biopsy sample of psoriasis vulgaris patients The mRNA expression of CARD14 was studied on 42 psoriasis lesional (case) and non-lesional (control) skin tissues. The expression level revealed significantly higher expression of CARD14 in psoriasis lesions with average fold change 3.09 ± 0.381 in comparison to non-lesional (1.00 ± 0.288) skin of the same patients. The analysis indicates nearly 2-fold change in expression of lesional tissue. The top 10 samples with highest fold change in their expression is represented in Fig. 2. Fig. 2Expression of CADR14 in punch biopsy samples from patients with psoriasis vulgaris, in both lesional and non-lesional tissues. Expression of CADR14 in punch biopsy samples from patients with psoriasis vulgaris, in both lesional and non-lesional tissues. Immunohistochemical analysis of CARD14 Hematoxylin and Eosin (H&E) staining in psoriatic skin showing melanin pigment in basal layers of epidermis (Fig. 3A). The keratinocytes of the psoriatic epidermis exhibited positive cytoplasmic staining when CARD14 was expressed. In the basal layer of psoriatic skin lesions, several labeled nuclei exhibit highly strong positive cytoplasmic staining (Fig. 3B). CARD14 immunoreactivity is observed at regular intervals in the non-lesional epidermis. Different layers of the epidermis showed CARD14 positivity, and the immunostaining was localized in both the nuclear and cytoplasmic regions (Fig. 3C). When comparing the epidermis of lesional psoriasis to non-lesional epidermis, a decrease in CARD14 expression was seen in specific regions, especially in the basal cell and upper granular layers of the epidermis (Fig. 3D). Figure 3E, represents photomicrograph from uninvolved skin showing absence of CARD14 expression in epidermal keratinocytes. Fig. 3(A) Hematoxylin and Eosin (H&E) staining in psoriatic skin showing melanin pigment in basal layers of epidermis (H&E; 100X). (B) CARD14 positivity is seen in epidermal keratinocytes (IHC; 200X). (C) CARD14 positivity is seen in endothelial cells of blood vessels (IHC; 100X). (D) Photomicrograph shows CARD14 positivity (IHC; 400X). (E) Photomicrograph from uninvolved skin showing absence of CARD14 in keratinocytes. (IHC; 200X). (A) Hematoxylin and Eosin (H&E) staining in psoriatic skin showing melanin pigment in basal layers of epidermis (H&E; 100X). (B) CARD14 positivity is seen in epidermal keratinocytes (IHC; 200X). (C) CARD14 positivity is seen in endothelial cells of blood vessels (IHC; 100X). (D) Photomicrograph shows CARD14 positivity (IHC; 400X). (E) Photomicrograph from uninvolved skin showing absence of CARD14 in keratinocytes. (IHC; 200X). Consequently, the epidermis of psoriatic skin lesions showed a substantial increase in CARD14 expression, according to the immunohistochemistry investigations. The association of CARD14 expression and distribution patterns suggested that lesional psoriatic skin samples had higher levels of CARD14 than non-lesional samples. These immunohistochemistry investigation results were consistent with the variant and expression analysis, corroborating the reported upregulation of CARD14 in severe psoriasis. Discussion The CARD14 gene also recognized as CARMA2 and belonging to the CARMA family, maintains conservation across various species. Psoriasis samples with CARD14 mutations exhibit elevated NF-kB activation, which causes keratinocytes to express more CCL20 and IL-8. It has recently come to light that CARD14 plays a pivotal role in the onset of psoriasis. The basal and suprabasal layers of the normal skin epidermis contain most of this gene. But in psoriatic skin that has lesions, it is less prevalent in the basal layer and more widely expressed in the suprabasal layers of the epidermis. This study revealed the eupregulation of CARD14 in both keratinocytes and endothelial cells. However, keratinocytes expressed CARD14 at higher levels than endothelial cells, indicating that keratinocytes may play a more important role in the pathophysiology of psoriasis than endothelial cells. Sometimes, gain-of-function mutations in CARD14 initiate a cascade of events wherein keratinocytes recruit inflammatory cells after a potentially epidermal-damaging triggering event. This initiates a continuous cycle of skin inflammation and regrowth, which is the hallmark of psoriasis. This pioneering study on the CARD14 gene is the first of its kind conducted on psoriatic patients within the Indian population, with no prior reports on this gene. The anticipation is that the expression of CARD14 is an early event in the development of psoriasis. This expression analysis was conducted on 42 cases of PsV, encompassing both lesional and non-lesional samples. Out of these, 38 cases showed a considerable upregulation of the CARD14 gene. The expression level indicated significantly higher expression in psoriasis lesions, with an average fold change of 3.09 ± 0.381 compared to the non-lesional skin (1.00 ± 0.288) of the same patients, signifying a twofold change in expression in lesional tissue. We observed that CARD14 expression is elevated in early-onset cases compared to Late-onset cases. The development of the immune system has been linked to the genes associated with the NF-kB pathway. This implies that there might be broad impacts on the transcriptional profile of squamous cell epithelia in general, which could facilitate the regenerative or wound-healing response in psoriatic keratinocytes. In this investigation, we assessed the expression levels of the CARD14 gene in individuals with moderate to severe cases of PsV. Immunohistochemistry validated the CARD14 gene expression in 42 samples. The results showed that psoriatic skin lesions overexpressed the CARD14 protein in comparison to non-lesional areas. This result is consistent with that of Jordan et al., who found that psoriatic lesions had higher expression of CARD14 in their study involving a Western population. The current work concludes by showing that CARD14 gene expression analysis using qRT-PCR has been carried out to support the role of the CARD14 gene as a therapeutic target and possible psoriasis biomarker. The outcomes of this study align with the results from genetic linkage studies on CARD14 in the Western population, paving the way for advancing drug development for this chronic disease. Both inflammation and psoriatic epidermal hyperproliferation may be induced by the overexpression of the CARD14 gene in psoriasis lesions. The expression of the CARD14 gene is positively confirmed by immunohistochemistry in moderate to severe cases of Indian psoriasis patients, highlighting the gene’s critical role in the onset and progression of the illness. Conclusions In our study, we found out the positive association of CARD14 with PsV, with statistical significance—firstly reported gene variants in India. To investigate the differential expression of candidate genes in disease, we conducted quantitative RT-PCR analysis between lesional skin and adjacent unaffected skin of plaque psoriasis patients. Interestingly, here we observed that our candidate genes show significantly up-regulated pattern just in similar way reported in western and ethnic population. Hence, we can conclude that mutations in candidate genes may trigger the over expression of genes at mRNA level. These observations positively validated through immuno-histochemical studies, thus provided evidence for the concept of combined effect of genetic and epigenetic factors in plaque psoriasis. These observations led us to conclude on the possible heterogeneity between genetic factors, and that they should be studied separately to detect other disease predisposing factors. Furthermore, this molecular expression study supports previous reports in psoriasis showing increased expression of CARD14 gene in psoriasis that have been shown to be an effective target in psoriasis in other studies. Present study has identified NF-kB signaling pathway playing vital role in immunopathogenesis of psoriasis disease by supporting genomic and proteomic function thus displaying strong potential as candidate therapeutic target in treatment of PsV. We found that CARD14 positively associated with psoriasis where the average expression of these genes was higher in females. No studies are available on association of CARD14 with Indian PsV patients, which is not sufficient in validating our results. Assessment of candidate gene markers may predict the therapy outcome in various ethnic populations. Our study thus showed genetic association of CARD14 and its combined effect in threat of developing PsV among Indian patients. Possible functional role of the genetic variants in disease development was also investigated. Combining genetic and proteomic associations revealed novel insights into psoriasis development mechanisms which can be utilized and targeted in future to invent specific therapeutic strategies and lead to better clinical management of plaque psoriasis. Future perspectives To explore the particular functional role of the SNPs or variants associated with plaque psoriasis, they can be hosted into normal keratinocyte cell lines to study the phenotypic and gene expression changes within the cells. This might help to deduce the actual importance of the SNPs in plaque psoriasis. Therapeutics used for psoriasis has often been found to be ineffective for long-term cure or causing side effects. Correlation between the inherent polymorphisms and drug response of the patient can be used to identify if these SNPs can dictate drug response, thereby leading to development of personalized therapy in psoriasis. To investigate whole exome sequencing or Next Gen Sequencing of candidate genes to identify additional disease-causing variants in Indian Population, which could be further, studied in- vivo for drug designing. Differential expression analysis revealed level of gene’s expression. Silencing these gene products in cell line models might help to understand their role in psoriasis and their potential as therapeutic targets. Exploring the IHC characterization of plaque psoriasis will help dermatologists to better understand the pathogenesis of most frequently present sub type of psoriasis and help clinicians optimize treatments.